首页>投融资
Foghorn Therapeutics
增发
Foghorn Therapeutics Inc.成立于2015年10月。该公司率先发现并开发了一类针对染色质调节系统内基因决定依赖性的药物，这是一个尚未开发的治疗机会干预。该公司专有的基因流量控制平台为其提供了一个对染色质调节系统的各个组成部分如何相互作用的综合性、机械性理解，使其能够识别、验证系统内的潜在药物靶点。
基本信息
-
公司全称Foghorn Therapeutics Inc
-
类型遗传性疾病治疗药物研发商
-
产业领域药品研发/制造、生物药、化学药
-
公司人数101~500人
-
地址500 Technology Square Ste 700 Cambridge MA 02139
-
联系电话1-617-5863100
-
邮箱info@foghorntx.com
-
成立时间2015-01-01
投融资
-
2024-05-22增发1.1亿美元Flagship PioneeringDeerfieldBVF Partners
-
2020-10-23上市1.12亿美元未透露
-
2020-02-25C轮2500万美元Saudi Aramco Energy VenturesRobert Bosch Venture CapitalDell Technologies CapitalIntel CapitalForté VenturesGE VenturesMarch Capital PartnersDarling VenturesCambridge AngelsHopewell Ventures
-
2019-05-12未公开6100万美元未透露
-
2018-03-13未公开5000万美元Flagship Pioneering
-
2017-10-04B轮3000万美元General ElectricSaudi Aramco Energy VenturesHive GroupRobert Bosch Venture CapitalHoneywell Venture CapitalIntel CapitalMarch Capital PartnersDarling VenturesYokogawa ElectricDell
-
2017-05-15A轮(A2)300万美元Dell Technologies CapitalSaudi Aramco Energy Ventures
-
2016-07-27A轮(A1)1200万美元Robert Bosch Venture CapitalDell Technologies CapitalGE VenturesMarch Capital PartnersDarling VenturesYokogawa Electric
-
2015-09-23种子轮250万美元March Capital Partners
- 加载更多
相关投融资企业
D轮
Circle Pharma is a biotechnology company focused on developing cell-permeable macrocyclic peptides against therapeutic targets using computational design and synthetic chemistry.In January 2016, Circle relocated to office and laboratory space in South San Francisco, CA.In June 2021, the company raised USD 66 million in an oversubscribed Series C financing.In March 2020, the company had raised USD 45 million in a series B financing round.In December 2016, the company issued USD 4.5 million shares of Series A preferred stock in a Series A financing round. In April 2017, the series A financing comprised of USD 6.5 million shares of series A preferred stock, was closed.In January 2016, the company extended its seed funding round with an investment from ShangPharma Investment Group
A轮
Gluetacs Therapeutics is a pharmaceutical company focused on protein degradation technology
增发
Foghorn Therapeutics Inc.成立于2015年10月。该公司率先发现并开发了一类针对染色质调节系统内基因决定依赖性的药物，这是一个尚未开发的治疗机会干预。该公司专有的基因流量控制平台为其提供了一个对染色质调节系统的各个组成部分如何相互作用的综合性、机械性理解，使其能够识别、验证系统内的潜在药物靶点。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息